Cargando…
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
Specimens of formalin-fixed, paraffin-embedded non-small-cell lung carcinomas (NSCLCs; n = 187) were analysed immunohistochemically for expression of cyclin A. The analysis was intended to determine whether cyclin A has additional prognostic value for predicting patients' survival and drug resp...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223613/ https://www.ncbi.nlm.nih.gov/pubmed/9192980 |
_version_ | 1782149431313825792 |
---|---|
author | Volm, M. Koomägi, R. Mattern, J. Stammler, G. |
author_facet | Volm, M. Koomägi, R. Mattern, J. Stammler, G. |
author_sort | Volm, M. |
collection | PubMed |
description | Specimens of formalin-fixed, paraffin-embedded non-small-cell lung carcinomas (NSCLCs; n = 187) were analysed immunohistochemically for expression of cyclin A. The analysis was intended to determine whether cyclin A has additional prognostic value for predicting patients' survival and drug response. Of the 187 NSCLCs, 141 cases (75%) showed expression of cyclin A. Patients with cyclin A-positive carcinomas had significantly shorter median survival times than patients with cyclin A-negative carcinomas (79 vs 129 weeks, P = 0.045). Similar results were obtained with more homogeneous groups of patients: patients with only T3 tumours, patients with epidermoid carcinomas and patients with lymph node involvement. The clinical parameters (age, stage, histology, extent of tumour size, lymph node involvement) had no influence on expression of cyclin A. A direct correlation between cyclin A and the proportion of S-phase cells (P = 0.08) and an inverse relationship between cyclin A and the proportion of G0/G1-phase cells (P = 0.04) were found. Furthermore, a significant correlation between the expression of cyclin A and the response of NSCLC to doxorubicin in vitro was detected (P = 0.026). IMAGES: |
format | Text |
id | pubmed-2223613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1997 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22236132009-09-10 Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Volm, M. Koomägi, R. Mattern, J. Stammler, G. Br J Cancer Research Article Specimens of formalin-fixed, paraffin-embedded non-small-cell lung carcinomas (NSCLCs; n = 187) were analysed immunohistochemically for expression of cyclin A. The analysis was intended to determine whether cyclin A has additional prognostic value for predicting patients' survival and drug response. Of the 187 NSCLCs, 141 cases (75%) showed expression of cyclin A. Patients with cyclin A-positive carcinomas had significantly shorter median survival times than patients with cyclin A-negative carcinomas (79 vs 129 weeks, P = 0.045). Similar results were obtained with more homogeneous groups of patients: patients with only T3 tumours, patients with epidermoid carcinomas and patients with lymph node involvement. The clinical parameters (age, stage, histology, extent of tumour size, lymph node involvement) had no influence on expression of cyclin A. A direct correlation between cyclin A and the proportion of S-phase cells (P = 0.08) and an inverse relationship between cyclin A and the proportion of G0/G1-phase cells (P = 0.04) were found. Furthermore, a significant correlation between the expression of cyclin A and the response of NSCLC to doxorubicin in vitro was detected (P = 0.026). IMAGES: Nature Publishing Group 1997 /pmc/articles/PMC2223613/ /pubmed/9192980 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Volm, M. Koomägi, R. Mattern, J. Stammler, G. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. |
title | Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. |
title_full | Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. |
title_fullStr | Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. |
title_full_unstemmed | Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. |
title_short | Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. |
title_sort | cyclin a is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223613/ https://www.ncbi.nlm.nih.gov/pubmed/9192980 |
work_keys_str_mv | AT volmm cyclinaisassociatedwithanunfavourableoutcomeinpatientswithnonsmallcelllungcarcinomas AT koomagir cyclinaisassociatedwithanunfavourableoutcomeinpatientswithnonsmallcelllungcarcinomas AT matternj cyclinaisassociatedwithanunfavourableoutcomeinpatientswithnonsmallcelllungcarcinomas AT stammlerg cyclinaisassociatedwithanunfavourableoutcomeinpatientswithnonsmallcelllungcarcinomas |